Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 75, Issue 6, Pages 1057-1064
Publisher
BMJ
Online
2015-12-16
DOI
10.1136/annrheumdis-2015-208279
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib
- (2014) Deepti Vyas et al. ANNALS OF PHARMACOTHERAPY
- Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro
- (2014) Sheau-Pey Wang et al. ANNALS OF THE RHEUMATIC DISEASES
- JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical
- (2014) Yoshiya Tanaka et al. Modern Rheumatology
- Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study
- (2014) Yoshiya Tanaka et al. Modern Rheumatology
- The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells
- (2013) Satoshi Kubo et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
- (2013) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis
- (2012) Y Tanaka et al. ANNALS OF THE RHEUMATIC DISEASES
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Pathogenesis of Rheumatoid Arthritis
- (2011) Iain B. McInnes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
- (2009) Andrea Rubbert-Roth et al. ARTHRITIS RESEARCH & THERAPY
- Intracellular signal pathways: Potential for therapies
- (2009) Melissa Mavers et al. Current Rheumatology Reports
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now